Affimed is a clinical-stage biopharmaceutical company headquartered in Heidelberg, Germany, developing innate cell engager (ICE) therapies for oncology. Its proprietary tetravalent bispecific antibody platform redirects NK cells and macrophages to tumor cells by binding CD16A on innate immune effector cells and tumor-associated antigens such as EGFR (AFM24) and CD123 (AFM28). Affimed trades on NASDAQ under the ticker AFMD.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2014
Sep 2014
Oct 2012
Apr 2010
Apr 2007
Jan 2003
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
